FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913426254> ?p ?o ?g. }

• W2913426254 endingPage "2354" @default.
• W2913426254 startingPage "2354" @default.
• W2913426254 abstract "Abstract Background: Vaso-occlusive processes in sickle cell anemia (SCA) are triggered by inflammatory molecules, along with pancellular activation and the recruitment and adhesion of leukocytes to the endothelium. Interactions between platelets, neutrophils, and erythrocytes are observed in the SCA circulation, but the exact role of platelets in the initiation and propagation of vaso-occlusion is not well understood. Aim: We, herein, evaluated the effects of the inhibition of platelet activation on TNF-α (TNF)-triggered vaso-occlusive processes in the microcirculation of mice with SCA, using prasugrel, a platelet ADP P2Y12 receptor inhibitor. Methods: Chimeric male control (CON) and SCA (SCA) mice received prasugrel (1 mg/kg, by gavage) or vehicle (saline) in a single administration, 1h prior to TNF (0.5 μg/g, i.p). In some experiments, 1 mg/kg prasugrel was administered chronically for 5x per week for 4 weeks. Following i.v. injection of anti-CD41 PE, anti-CD45 PeCy-5 and anti-Ly6G Alexa 488 antibodies for labeling platelets, leukocytes (in general) and neutrophils respectively, the cremaster muscle was exposed and the microcirculation was observed by conventional and confocal intravital microscopy. Results: While the acute administration of prasugrel to CON and SCA mice did not alter the quantity of platelets in the microcirculation (data not shown), it significantly reduced the adhesion of platelets to the vascular wall in both CON animals (12±1.6 vs 5.7±1.4 % adhered of total platelets, n=3; p<0.05) and SCA mice after TNF (36.2±7.1 vs 4.8±2.5 % platelets adhered for w/out and with prasugrel, respectively; n=3; p<0.0001) (see Figure). Furthermore, prasugrel significantly reduced the number of platelet/neutrophil aggregates in TNF-treated CON (2.7±0.4 vs 0.53±0.3 aggregates adhered 100 µm−1, p<0.001 n=3) and SCA mice (3.1±0.7 vs 0.76±0.3 aggregates adhered 100 µm−1, p<0.01 n=3), and also platelet/non-neutrophil leukocytes in CON (1.3±0.7 vs 0.2±0.1 aggregates adhered 100 µm−1, p<0.01 n=3) and SCA mice (2.0±0.3 vs 0.2±0.1 aggregates adhered 100 µm−1, p<0.001 n=3). Alterations in platelet adhesion to the vascular wall and platelet-leukocyte aggregate formation were accompanied by reductions in the recruitment of leukocytes to the venule walls, after prasugrel administration. Prasugrel significantly decreased the rolling, adhesion and extravasation of leukocytes in both CON (4.9±2.7 vs 1.14±0.5 min−1; 9.2±0.8 vs 2.7±0.5 100 µm−1; 1.9±0.3 vs 0.4±0.1 100x50 µm-2; for w/out and with prasugrel, respectively; n=3; p<0.001) and SCA mice (36.0±3.0 vs 3.0±0.6 min−1; 16.6±1.5 vs 6.4±1.2 100 µm−1; 6.9±0.8 vs 1.7±0.4 100x50 µm-2; for w/out and with prasugrel, respectively; n=3; p<0.0001). Acute prasugrel treatment also increased blood flow velocity after TNF stimulation in CON mice (37±10 vs 110±35 mm3/s, p<0.01, n=3) and substantially augmented flow in SCA mice (13±2 vs 94±12 mm3/s, p<0.0001, n=3), approaching flow velocities similar to those observed in control animals that had not received TNF (Data not shown). The survival of SCA animals treated with a single dose of prasugrel increased by 1.3 hours compared to the SCA animals that received the vehicle (n=3, p<0.05). Complimentary experiments demonstrated a similar effect of the chronic administration of prasugrel, which significantly reduced leukocyte recruitment to the vascular wall after TNF in both CON and SCA mice (data not shown, P<0.05). Conclusions: Our findings show that the inhibition of platelet activation by prasugrel, while significantly decreasing the adhesion of platelets to venules walls and the formation of heterocellular aggregates, was able to almost abolish the recruitment of leukocytes to the microcirculation of SCA mice after an inflammatory stimulus. This reduction in platelet and leukocyte vascular recruitment was associated with major improvements in blood flow and in the survival of animals with SCA. Thus, our data suggest that platelet activation and the consequent adhesion of platelets to the vascular wall is a fundamental step in the initiation of the vaso-occlusive process in response to inflammatory stimuli. Our findings support further investigations into the use of drugs that inhibit platelet activation (including prasugrel itself) as a therapeutic approach for SCA. Disclosures No relevant conflicts of interest to declare." @default.
• W2913426254 created "2019-02-21" @default.
• W2913426254 creator A5000536583 @default.
• W2913426254 creator A5010068407 @default.
• W2913426254 creator A5032661283 @default.
• W2913426254 creator A5047823900 @default.
• W2913426254 creator A5050058477 @default.
• W2913426254 creator A5067515209 @default.
• W2913426254 creator A5067713063 @default.
• W2913426254 creator A5071663197 @default.
• W2913426254 creator A5072947508 @default.
• W2913426254 creator A5084195232 @default.
• W2913426254 creator A5086831315 @default.
• W2913426254 date "2018-11-29" @default.
• W2913426254 modified "2023-10-16" @default.
• W2913426254 title "TNF-Induced Vaso-Occlusive and Inflammatory Processes in Mice with Sickle Cell Anemia Are Abrogated By the Platelet Activation Inhibitor, Prasugrel" @default.
• W2913426254 doi "https://doi.org/10.1182/blood-2018-99-118633" @default.
• W2913426254 hasPublicationYear "2018" @default.
• W2913426254 type Work @default.
• W2913426254 sameAs 2913426254 @default.
• W2913426254 citedByCount "0" @default.
• W2913426254 crossrefType "journal-article" @default.
• W2913426254 hasAuthorship W2913426254A5000536583 @default.
• W2913426254 hasAuthorship W2913426254A5010068407 @default.
• W2913426254 hasAuthorship W2913426254A5032661283 @default.
• W2913426254 hasAuthorship W2913426254A5047823900 @default.
• W2913426254 hasAuthorship W2913426254A5050058477 @default.
• W2913426254 hasAuthorship W2913426254A5067515209 @default.
• W2913426254 hasAuthorship W2913426254A5067713063 @default.
• W2913426254 hasAuthorship W2913426254A5071663197 @default.
• W2913426254 hasAuthorship W2913426254A5072947508 @default.
• W2913426254 hasAuthorship W2913426254A5084195232 @default.
• W2913426254 hasAuthorship W2913426254A5086831315 @default.
• W2913426254 hasBestOaLocation W29134262541 @default.
• W2913426254 hasConcept C126322002 @default.
• W2913426254 hasConcept C12722491 @default.
• W2913426254 hasConcept C203014093 @default.
• W2913426254 hasConcept C2777028646 @default.
• W2913426254 hasConcept C2777628954 @default.
• W2913426254 hasConcept C2777849778 @default.
• W2913426254 hasConcept C2778620579 @default.
• W2913426254 hasConcept C2779134260 @default.
• W2913426254 hasConcept C2859252 @default.
• W2913426254 hasConcept C2993802102 @default.
• W2913426254 hasConcept C3018697912 @default.
• W2913426254 hasConcept C49059817 @default.
• W2913426254 hasConcept C71924100 @default.
• W2913426254 hasConcept C89560881 @default.
• W2913426254 hasConcept C98274493 @default.
• W2913426254 hasConceptScore W2913426254C126322002 @default.
• W2913426254 hasConceptScore W2913426254C12722491 @default.
• W2913426254 hasConceptScore W2913426254C203014093 @default.
• W2913426254 hasConceptScore W2913426254C2777028646 @default.
• W2913426254 hasConceptScore W2913426254C2777628954 @default.
• W2913426254 hasConceptScore W2913426254C2777849778 @default.
• W2913426254 hasConceptScore W2913426254C2778620579 @default.
• W2913426254 hasConceptScore W2913426254C2779134260 @default.
• W2913426254 hasConceptScore W2913426254C2859252 @default.
• W2913426254 hasConceptScore W2913426254C2993802102 @default.
• W2913426254 hasConceptScore W2913426254C3018697912 @default.
• W2913426254 hasConceptScore W2913426254C49059817 @default.
• W2913426254 hasConceptScore W2913426254C71924100 @default.
• W2913426254 hasConceptScore W2913426254C89560881 @default.
• W2913426254 hasConceptScore W2913426254C98274493 @default.
• W2913426254 hasIssue "Supplement 1" @default.
• W2913426254 hasLocation W29134262541 @default.
• W2913426254 hasOpenAccess W2913426254 @default.
• W2913426254 hasPrimaryLocation W29134262541 @default.
• W2913426254 hasRelatedWork W1468775069 @default.
• W2913426254 hasRelatedWork W1693250771 @default.
• W2913426254 hasRelatedWork W2012111144 @default.
• W2913426254 hasRelatedWork W2083443460 @default.
• W2913426254 hasRelatedWork W2200280708 @default.
• W2913426254 hasRelatedWork W2492085083 @default.
• W2913426254 hasRelatedWork W2739317526 @default.
• W2913426254 hasRelatedWork W2794538630 @default.
• W2913426254 hasRelatedWork W2913426254 @default.
• W2913426254 hasRelatedWork W4315754538 @default.
• W2913426254 hasVolume "132" @default.
• W2913426254 isParatext "false" @default.
• W2913426254 isRetracted "false" @default.
• W2913426254 magId "2913426254" @default.
• W2913426254 workType "article" @default.